Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Publication Title
British journal of haematology
Document Type
Article
Publication Date
5-1-2019
Keywords
LYRA; bortezomib; cyclophosphamide; daratumumab; multiple myeloma
Abstract
This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D-VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4-8 induction cycles of bortezomib 1·5 mg/m
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Hematology
COinS
